Skip to content
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact

Investing in People With Vision

It takes a village to bring life-saving medicines to market, so we invest in entrepreneurs to create companies that turn breakthroughs into treatments for patients in need. 

W Hero Image

We Put People First

Westlake BioPartners is a people-first life science VC firm that crafts companies around world-class entrepreneurs. Immersed in the Los Angeles biotech community we helped catalyze, we’re intentionally scaled to incubate only the most promising companies by complementing their teams with personal attention, hands-on support, and connections to the most impactful innovations of our time. We believe it takes more than just great science to make life-changing medicines and by putting people first, we serve the greatest unmet patient needs.

Get to Know Our People

Our Entrepreneurs Making a Difference

Peter Anastasiou, CEO, Capsida Biotherapeutics

Peter Anastasiou,
CEO

Viviana Gradinaru, Founder/Caltech

Viviana Gradinaru,
Founder/Caltech

Capsida Biotherapeutics

Creating a new class of targeted gene therapies for patients with debilitating and life-threatening genetic disorders.

Kathy Dong

Kathy Dong,
CEO

Electra Therapeutics

Developing a new way to change lives through a unique vision of mastering signal regulatory proteins (SIRP).

Company We’re Proud to Keep

The Westlake Way

We know people are the first and most valuable asset. Our approach focuses on empowering the right entrepreneurs and guiding them through growth from ideation and preclinical research to clinical and commercial impact for the treatment of patients. We’re intentionally scaled to foster close relationships with our founders, take action instead of offer opinions, and deepen harmonious connections in our entrepreneurial network. By committing to personal attention, we provide each member of our concentrated portfolio with equal and essential access to innovation, capital, and community.

Learn About Our Approach

Happenings in Our Network

Portfolio News

Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease

June 24, 2025
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2...
Read More
Portfolio News

Capsida Receives FDA IND Clearance for Its IV-Administered Gene Therapy for Parkinson’s Disease Associated with GBA Mutations

June 11, 2025
Capsida is initiating the Phase 1/2 study for CAP-003, with the...
Read More
Portfolio News

Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

May 14, 2025
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance...
Read More
See All the Latest

A Complementary Community

Where our visionary founders seized the opportunity to propel the Los Angeles biotech ecosystem, we’ve continued to build an increasingly symbiotic and ever-evolving community. From finding the right entrepreneurs to spearhead company formation, to scaling science through phase-appropriate R&D resources, our network provides unique complementary connections. Drawing from these roots, we support people making medical breakthroughs in California and beyond.

Thinking of the next breakthrough?

Join Our Community
  • People
  • Portfolio
  • About
  • News
  • Contact

© 2025 Westlake BioPartners. All Rights Reserved. Privacy Policy